The goal of this observational study is to learn about the long-term effects of aortic valve annular calcification in patients undergoing transcatheter aortic valve replacement (TAVR). The main question it aims to answer is:
Does the degree of aortic valve annular calcification prior to TAVR influence long-term clinical outcomes, including major adverse cardiovascular events including all-cause mortality, over a 3-year period?
Participants who have undergone TAVR as part of their regular medical care for severe aortic stenosis will have their pre-procedural imaging and clinical outcomes evaluated for a 3-year follow-up period.
Adults aged 19 years or older.
Patients who have undergone transcatheter aortic valve replacement (TAVR) for severe aortic stenosis.
Individuals who have voluntarily provided written informed consent to participate.
None
Adults aged 19 years or older who have undergone transcatheter aortic valve replacement (TAVR) for severe aortic stenosis and have voluntarily expressed their willingness to participate through written informed consent.
Cohort
Prospective
Transcatheter aortic valve replacement with ballon-expandable or self-expandable valves
DeviceDevice: Edwards SAPIEN 3 valve, Medtronic Evolut valve, Boston Acurate Neo valve, or Abbott Navitor Access route: transfemorak, subclavian, transapical, transcarotid, or transcaval The use of balloon dilation will be left to the discretion of the operator.
All-cause mortality
Hospitalization for heart failure
Stroke
Myocardial infarction
Permanent pacemaker insertion
Echo parameters
Click on the lead sponsor to view all of their trials.
